Hussman Strategic Advisors’s Harmony Biosciences HRMY Stock Holding History

Hussman Strategic Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-84,000	Closed	-$2.35M	–	274
2026 Q1	$2.35M	Buy	84,000 +21,000	+33%	+$689K	0.51%	74
2025 Q4	$2.36M	Buy	63,000 +21,000	+50%	+$690K	0.57%	64
2025 Q3	$1.16M	Sell	42,000 -63,000	-60%	-$2.17M	0.25%	173
2025 Q2	$3.32M	Buy	105,000 +21,000	+25%	+$676K	0.76%	34
2025 Q1	$2.79M	Hold	84,000	–	–	0.68%	36
2024 Q4	$2.89M	Buy	84,000 +21,000	+33%	+$722K	0.85%	25
2024 Q3	$2.52M	Buy	63,000 +42,000	+200%	+$1.48M	0.62%	54
2024 Q2	$634K	Hold	21,000	–	–	0.17%	178
2024 Q1	$705K	Hold	21,000	–	–	0.16%	166
2023 Q4	$678K	Sell	21,000 -10,000	-32%	-$279K	0.15%	175
2023 Q3	$1.02M	Hold	31,000	–	–	0.19%	195
2023 Q2	$1.09M	Hold	31,000	–	–	0.2%	202
2023 Q1	$1.01M	Buy	+31,000	New	+$1.41M	0.16%	214

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hussman Strategic Advisors's HRMY Position: Q2 2026 in Review

Hussman Strategic Advisors sold out of Harmony Biosciences (HRMY) in Q2 2026, closing a stake of 84,000 shares — an estimated $2.35M sold.

Hussman Strategic Advisors first reported a position in HRMY in Q1 2023 and held it in 13 quarters. The position peaked at $3.32M in Q2 2025. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

Hussman Strategic Advisors reported no remaining Harmony Biosciences position as of Q2 2026 after selling out during the quarter.
Hussman Strategic Advisors sold 84,000 Harmony Biosciences shares in Q2 2026, an estimated $2.35M.
Hussman Strategic Advisors first reported a position in Harmony Biosciences in Q1 2023 and held it in 13 quarters.
Hussman Strategic Advisors's Harmony Biosciences position peaked at $3.32M in Q2 2025.
327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.